Sarsia is an early-stage venture capital firm We invest in a greener and healthier future
Reliability is at the core of what we doVisit page
Background in science, experience from industry
Sarsia strenght lies in our differences; people with diverse backgrounds, knowledge and experience giving different perspectives.Visit page
- Visit page
Our focus is on unmet medical needs. Where competence and capital are decisive when turning a laboratory result into an effective treatment for the patient.
- Visit page
Technology, Energy and Sustainability
We search for technologies and founders capable of accelerating the green transition and of building sustainable companies for the future.
A talent for value creation begins with the will to dare the unknown
Theories, hypotheses and research are rooted in ambition. Clear goals, systematic hard work and dedication create results. Sarsia focus on technologies that can improve the quality of life, society and reduce negative impact on nature. Sarsia creates value by linking good solutions and science with competent capital. We thrive on change, and dare to take risks to create value. This has made us one of the best performing VC firms in the Nordic countries.
- 17Years since startup
- 900mNOK (2 funds)
- 12600mNOK Portfolio IPEV Value
1140 companies screened
29 portfolio companies
Top performance among Norwegian Early Stage Venture funds
Two of the most valuable early stage venture backed companies in Norway.
It’s all about moving the planet forward
We are motivated by making a difference. By contributing to the development of technologies that have the potential to solve important challenges. That doesn’t always mean the easiest road to our goals. And achieving them requires both eagerness and endurance.
Mon Jan 02 2023
Coegin Pharma raises 25 mSEK
Coegin Pharma AB (COEGIN:Nordic GM) raises 25,3 mSEK through combined rights issue and directed new …Read full article
Fri Dec 16 2022
Rallybio publishes promising results with technology aquired from Prophylix Pharma
American biotech company Rallybio publishes proof-of-concept data from animal studies with technolog…Read full article
Tue Dec 06 2022
Nykode Therapeutics announces clinical collaboration with MSD
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination Wit…Read full article